A Potential Shift In FDA's Approach To Drug Trial Design
On Jan. 9, the U.S. Food and Drug Administration issued a draft guidance document, "Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products," which clarifies how Bayesian approaches may be...To view the full article, register now.
Already a subscriber? Click here to view full article